This study looks at the long-term use of a drug called KarXT for people with Alzheimer's disease who also have psychosis, which means seeing or hearing things that aren't there. It's called an Open-Label Extension Study, meaning everyone knows what medicine they're taking. The study is for people who already finished certain earlier studies (CN012-0026, CN012-0027, or CN012-0056). This study lasts for a year (52 weeks) and the main goal is to see if KarXT is safe and how well people can tolerate it over a long time.

• The study lasts 52 weeks, so participants should be ready for a year-long commitment.
• Participants must have stable living conditions and may need approval if moving to a nursing home.
• Participants cannot join if they have other significant medical issues or are in another study.